Linaclotide is a synthetic, 14-amino acid peptide analog of the endogenous hormones guanylin and uroguanylin. It was rationally designed as a potent and selective agonist of the guanylate cyclase-C (GC-C) receptor, which is expressed on the luminal surface of intestinal epithelial cells. Its discovery stemmed from research into the guanylin peptide family’s role in regulating intestinal fluid secretion and transit. Linaclotide is significant as the first-in-class GC-C agonist approved for the treatment of chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C), representing a targeted, peripherally-acting therapy with minimal systemic absorption. Its mechanism provides a physiological approach to managing functional gastrointestinal disorders by leveraging the body’s intrinsic signaling pathways.
Quick Facts
| Also Known As | MD-1100, Guanylate cyclase-C agonist peptide |
|---|---|
| Sequence | Cys-Cys-Glu-Tyr-Cys-Cys-Asn-Pro-Ala-Cys-Thr-Gly-Cys-Tyr (Disulfide bonds: Cys1-Cys6, Cys2-Cys10, Cys5-Cys13) |
| Molecular Formula | C59H79N15O21S6 |
| Molecular Weight | 1526.8 Da |
| PubChem CID | 16158208 |
Research Parameters
| Half-Life | Not applicable in systemic terms; acts locally in the gastrointestinal tract with minimal systemic absorption. |
|---|---|
| Stability | As an approved oral drug product, it is formulated in a stable gelatin capsule. For research-grade peptide material in lyophilized form, typical stability is 24 months when stored at -20°C. Reconstituted solutions are not standard for this peptide due to its oral formulation. |
| Solubility | Not applicable for standard research reconstitution; formulated for oral delivery in capsules. |
| Storage (Lyophilized) | -20°C, protect from light and moisture (for research-grade raw material). |
| Storage (Reconstituted) | Not standard; the clinical product is stored at room temperature in its final capsule form. |
| Typical Research Dose | 145-290 mcg (oral, once daily) |
| Cycle Parameters | Continuous daily oral administration, as studied in clinical trials for CIC and IBS-C. |
| Amino Acid Count | 17 |
Mechanism of Action
Linaclotide's primary mechanism of action is the selective activation of guanylate cyclase-C (GC-C) receptors on the luminal surface of intestinal epithelial cells. This activation triggers a well-defined intracellular signaling cascade that results in increased luminal fluid secretion and accelerated intestinal transit.
GC-C Receptor Activation: Linaclotide binds to and activates the GC-C receptor, a transmembrane enzyme located on the apical membrane of enterocytes from the duodenum to the rectum.
cGMP Production: Receptor activation stimulates the intracellular production of cyclic guanosine monophosphate (cGMP). This second messenger accumulates within the enterocyte.
CFTR Channel Activation: Elevated intracellular cGMP activates the cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel. This leads to increased secretion of chloride and bicarbonate ions into the intestinal lumen.
Fluid Secretion & Transit: The ion secretion creates an osmotic gradient that draws water into the intestinal lumen, softening stool and increasing its volume. Additionally, linaclotide has been shown to reduce visceral hypersensitivity in animal models, potentially via cGMP-mediated inhibition of pain-sensing neurons, which contributes to its benefit in IBS-C.
Research Applications
Gastrointestinal Motility Disorders: Research demonstrates linaclotide's efficacy in increasing spontaneous bowel movements, improving stool consistency, and reducing straining in models of chronic constipation. Its action is localized to the intestine with minimal systemic exposure.
Irritable Bowel Syndrome with Constipation (IBS-C): Beyond pro-secretory effects, studies indicate linaclotide reduces abdominal pain and discomfort in IBS-C models. This is attributed to its ability to decrease visceral hypersensitivity through a cGMP-mediated desensitization of colonic nociceptors.
Preclinical Intestinal Inflammation Models: Some preclinical research has explored the potential cytoprotective and anti-inflammatory effects of GC-C activation in models of colitis, suggesting a role in maintaining epithelial barrier function, though this is not its primary clinical indication.
Safety & Side Effects
In clinical trials, the most common side effects are gastrointestinal in nature, including diarrhea (which can sometimes be severe), abdominal pain, flatulence, and abdominal distension. These are mechanism-based effects. Due to its minimal systemic absorption (less than 0.1%), systemic side effects are rare. Theoretical concerns based on the mechanism would involve excessive fluid and electrolyte loss in cases of severe diarrhea. It is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction.
Dosage Information
Disclaimer: The following information is derived from published clinical and preclinical research for educational purposes only. It does not constitute medical advice.
In human clinical trials for approved indications, the typical oral dose is 145 mcg or 290 mcg once daily on an empty stomach, at least 30 minutes before the first meal of the day. The peptide is administered orally in a capsule formulation designed for local action in the intestine. Research dosing is based on these established clinical protocols. The duration of administration in studies typically ranges from 12 to 26 weeks.
References
Bryant, A.P., Busby, R.W., Bartolini, W.P., et al. Linaclotide is a potent and selective guanylate cyclase C agonist that elicits pharmacological effects locally in the gastrointestinal tract. Life Sciences, 2010.
Castro, J., Harrington, A.M., Hughes, P.A., et al. Linaclotide inhibits colonic nociceptors and relieves abdominal pain via guanylate cyclase-C and extracellular cyclic guanosine 3',5'-monophosphate. Gastroenterology, 2013.
Lembo, A.J., Schneier, H.A., Shiff, S.J., et al. Two randomized trials of linaclotide for chronic constipation. The New England Journal of Medicine, 2011.
Rao, S., Lembo, A.J., Shiff, S.J., et al. A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation. The American Journal of Gastroenterology, 2012.
Busby, R.W., Bryant, A.P., Bartolini, W.P., et al. Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit. European Journal of Pharmacology, 2010.